Financial Reports and Presentations

2006

2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2005
All years

Presentations

Annual Reports
Interim Reports
Other
All types

	Report	Presentation	Webcast

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com